1. BIOMEDICA LIFE SCIENCES SA Expanding a commercial SME specializing in radiopharmaceuticals and high-tech medical imaging instrumentation into a dynamic group of Biotechnology companies

2. BIOMEDICA LIFE SCIENCES SA BIOMEDICA LIFE SCIENCES SA Established in 1994 Total number of employees: 29 2003 revenue from sales 4,016 mil €EBT 0,9 mil € Coupling BIOMEDICA’s management and marketing resources and expertise with excellence in biotechnological research of Greek Research Institutes and University Laboratories Main concept for the expansion:

3. Strategy Main Points and Objectives 1. Establishing the company’s R&D base through the collaboration with research groups in National Research Centres and Universities 2. Organizing and managing a state-of-the-art Radiopharmaceuticals Production Unit (GMP) based on the infrastructure and know-how of NCSR “Demokritos” 3. Designing, conducting and funding of multicenter clinical trials in Greece and abroad 4. Expanding into Molecular Diagnostics & Genetic Testing

4. 1.Establishing the R&D Base 1.Establishing the R&D Base Collaborating with the Greek Research Community I. Direct funding of novel research ideas in Radiopharmacy and Radiodiagnostics 1. Radiolabeled Biomolecules in Diagnosis and Therapy Tc 99m labelled bombesin, minigastrin and neurotensin analogues Principal Investigators: A. Varvarigou, NCSR “Demokritos” T. Maina, B. Nock, NCSR “Demokritos” Greek patents granted – European patents pending Tc 99m labelled YIGSR for radiodiagnosis & immunotherapy Principal Investigator:G. Koliakos, University of Thessalonica Greek patent granted – European patent granted 2. Peptide Design and Synthesis Principal Investigator: P. Cordopatis, University of Patras Greek patents granted – European patents pending

5. II. Participating as co-sponsor and/or end-user in selected research programs funded by GSRT and EU EKBAN 2003-2006 «Τεχνητά Χρωμοσώματα Εντομοιών (ΤΕΧΠΕΝ) και Τεχνολογίες για Γονιδιακή Θεραπεία και Συνεχή Υψηλού Επιπέδου Έκφραση Θεραπευτικών Πρωτεϊνών σε εντομικά Συστήματα Παραγωγής», ΕΚΕΦΕ «Δημόκριτος», Ινστιτούτο Pasteur, Biomedica, 582.000 € (budget of project, Biomedica participation 245.000 € ) ΗΡΩΝ 2003-2006 «Ανάπτυξη και αξιολόγηση ραδιοεπισημασμένων βιομορίων για διάγνωση ή/και θεραπεία νεοπλασιών διαφόρων μορφών» Biomedica, 264.000 € (granted by 50%) ΠΕΝΕΔ – ΔΙΑΚΡΑΤΙΚΕΣ ΣΥΝΕΡΓΑΣΙΕΣ

6. Biomedica Research Personnel May 2004 BIOMEDICA Funded Research Programs: 7 full time positions – 4 PhDs Co-Sponsored Research Programs: 5 full time positions – 4 PhDs

7. 2. Organizing and Managing a Radiopharmaceutical Production Unit A strategic alliance between BIOMEDICA and the Institute of Radioisotopes & Radiodiagnostic Products has been approved by the Board of Directors of NCSR “Demokritos” in May 2004

8. Joint Venture  Organization and Management of the Institute’s unique Infrastructure  Implementation of Good Manufacturing Practice (GMP) Protocols

9.  Production of selected highly demanded radiopharmaceuticals in Greece and abroad  Pilot production of novel products for clinical trials  Providing specialized GMP lyophilization services to third parties  Providing education and training

10. NCSR “Demokritos” Infrastructure  Class 100 lyophilization clean room  Radiochemical – Radiobiological Quality Control Labs  Hot-Cells A joint BIOMEDICA & NCSR “Demokritos” team will carry out development, production and QC of radiopharmaceuticals A joint BIOMEDICA & NCSR “Demokritos” team will carry out development, production and QC of radiopharmaceuticals

11. 4. Expanding into Molecular Diagnostics & Genetic Testing BioGenomica S.A BioGenomica S.A. Centre for Genetic Testing and Analyses A spin-off Company of NCSR “Demokritos” established in February 2004 The company’s business plan has been successfully incorporated in the PRAXE Phase B Program of GSRT with a total budget of 2 mil €.

12. BioGenomica SA BioGenomica SA Centre for Genetic Testing and Analyses a spin-off company of NCSR “Demokritos” Genetic testing for predisposition to hereditary diseases Cancer -Neurological and Psychiatric Disorders - Rare Diseases DNA sequencing tailoring specific laboratory needs Food industry – Public health

13.  Providing services to hospitals, clinics and diagnostic centres in Greece and abroad  Participation in international genetic testing networks  Providing services to the food and agricultural industry

14. June 2004: total number of employees: 6 (3 PhDs) State-of-the-art instrumentation: Automated DNA Sequencing, dHPLC, Real-time PCR and DNA microarray-based technologies  European Molecular Quality Network evaluation and accreditation

15. BioGenomica Research Establishment of International Scientific Advisory Board Design of clinical research protocols jointly with medical centers and collaborative groups and networks Participation in large-scale genetic epidemiology studies Incubation of basic science, biochemical and biophysical research projects jointly with Universities and Research Institutes